MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

This study is a prospective, open-label, phase I design.

Trial Details

NCT ID
NCT04808323
Phase
PHASE1
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Capecitabine
  • Initial Dose of Radiation before Dose Escalation
  • Cohort A: Dose Escalation Radiation
  • Cohort B: Dose Escalation Radiation
  • Cohort C: Dose Escalation Radiation
  • FOLFOX
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Pathologically confirmed (histologic or cytological), adenocarcinoma of the rectum.
  • Determined on staging evaluation to be clinical stage I, II or III.
  • No concerning unequivocal or biopsy-proven metastatic disease. Patients are eligible with either no evidence of distant metastatic disease, or "equ…
  • Eastern Cooperative Oncology Group (ECOG) status 0-2 within 45 days of study entry.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →